*In vivo* tumour proliferation rates, initially estimated from the percentages of either mitotic cells or S-phase cells, have long been known to be related at least for some tumour types to clinical outcome ([Tannock, 1978](#bib17){ref-type="other"}). Other estimates of proliferative activity, including staining with antibodies to antigens such as Ki-67 and PCNA, and more recently, gene expression profiles ([Nutt *et al*, 2003](#bib14){ref-type="other"}), have also been associated with clinical outcome in some studies. Potential tumour doubling times (*T*~pot~ values) rely on simultaneous measurement of S-phase percentage and S-phase duration and provide more quantitative estimates, which for many tumour types cover a range from 2 days to several weeks ([Wilson *et al*, 1988](#bib19){ref-type="other"}; [Rew and Wilson, 2000](#bib15){ref-type="other"}). However, although short *T*~pot~ values are generally related to poor prognosis, the value of *T*~pot~ as an independent prognostic indicator is controversial ([Haustermans and Fowler, 2001](#bib8){ref-type="other"}), and in the case of brain cancers, *T*~pot~ values are not clearly related to survival ([Danova *et al*, 1988](#bib7){ref-type="other"}; [Struikmans *et al*, 1998](#bib16){ref-type="other"}).

We have previously investigated the possibility that data from short-term cultures of clinical tumour material might have prognostic significance ([Marshall *et al*, 1992](#bib13){ref-type="other"}, [2003](#bib12){ref-type="other"}; [Baguley *et al*, 2002](#bib2){ref-type="other"}), and we were particularly interested in the possibility of using tumour material to estimate culture cycle time. Direct measurement in such cultures is impossible because of the presence of host cells in the sample and the loss of tumour cells, through apoptosis or other pathways, during primary culture. However, we had previously found using a series of human tumour cell lines that the degree of incorporation of ^3^H-thymidine into DNA at different times after addition of paclitaxel, an inhibitor of mitosis and cell division, was a function of the measured culture doubling time ([Baguley *et al*, 1995](#bib3){ref-type="other"}). We assumed that culture-doubling time was similar to culture cycle time for cell lines (i.e., that cell loss was negligible) and developed an empirical formula that related culture cycle time to the ^3^H-thymidine data.

We then considered whether the above formula, obtained using cell lines, might be applied to short-term (7-day) cultures of tumour samples obtained at surgery. The nature of the assay (comparison of ^3^H-thymidine incorporation with and without paclitaxel) minimised the consequences of tumour cell loss during culture because any cell loss would affect cultures with and without paclitaxel almost equally. Surprisingly, culture cycle times estimated in this manner were found to vary among individual samples from approximately 2 days to more than 40 days, a range that was remarkably similar to that obtained in *T*~pot~ measurements ([Baguley and Marshall, 2004](#bib1){ref-type="other"}). Furthermore, in a small study of 16 patients with ovarian cancer, derived culture cycle times were found to be related to patient survival ([Baguley and Marshall, 2004](#bib1){ref-type="other"}). Here, we have addressed the question of whether the same approach might be applied to patients with brain tumours. We cultured samples from a range of brain tumours and have also included melanomas metastatic to the brain, as they are also tumours derived from the neural crest. We then determined whether culture cycle times derived by this approach were related to overall survival.

Materials and methods
=====================

Culture of tumour samples
-------------------------

Patients received surgery in the Department of Neurosurgery, Auckland City Hospital. All studies were carried under guidelines approved by the Northern X Regional Ethics Committee, and informed consent was obtained from all patients. A portion of tumour tissue taken from patients undergoing surgery for brain malignancies was placed in *α*-MEM growth medium containing insulin (10 *μ*g/ml), transferrin (10 *μ*g/ml), selenite (10 ng/ml) and 5% fetal bovine serum and was used either immediately or after overnight storage at 4°C. Tumour material was disaggregated to form small cellular clusters to preserve, as far as possible, cell--cell and cell--matrix interactions ([Baguley *et al*, 2002](#bib2){ref-type="other"}). Preparations were monitored by phase contrast microscopy and by examination of haematoxylin/eosin-stained cytospins. Cell suspensions, containing both single cells and cell clusters, were transferred to 96-well tissue culture plates that had previously been coated with a thin layer of agarose to prevent the growth of fibroblasts and were grown at 37°C under an atmosphere of 5% O~2~, 5% CO~2~ and 90% N~2~ ([Marshall *et al*, 1992](#bib13){ref-type="other"}).

Determination of culture cycle times
------------------------------------

Plates were set up to contain between 940 and 7500 cells in a volume of 150 *μ*l, to allow selection of a cell density where ^3^H-thymidine incorporation after 7 days was proportional to the initial number of cells added. Cultures were grown either in the absence of drug or in the presence of paclitaxel at five 3-fold concentration steps up to a maximum of 2 *μ*[M]{.smallcaps}. S-phase cells remaining at the end of the incubation were labelled by the addition of ^3^H-thymidine over the last 24 h ([Baguley *et al*, 1995](#bib3){ref-type="other"}). Cultures were harvested and duplicate samples were analysed for each paclitaxel dose with multiple control samples. ^3^H-thymidine incorporation data in the presence of paclitaxel were fitted by a least-squares fit to an exponential of the form *y*=*P*+*a*e^−*b*x^, where *y* is the radioactivity (corrected for background), *x* is the paclitaxel concentration and *a* and *b* are variables, as shown in the two examples in [Figure 1](#fig1){ref-type="fig"}. Values of *P* therefore reflected the proportion of remaining S-phase cells at the end of the incubation period, which in turn reflected the proportion of G~1~-phase cells that were feeding into S-phase. The estimated culture cycle time in days (*T*) was calculated using an equation *T*=−3.78/(log~10~ *P*), which was derived from empirical data obtained with cell lines ([Baguley *et al*, 1995](#bib3){ref-type="other"}). When *P* was \>0.81 (*T*\>40), culture cycle time was not accurately provided by this formula and was arbitrarily set at 40 days.

Statistics
----------

Median culture cycle times were compared using the Kruskall--Wallis test, and proportions using a *χ*^2^ test. Survival was compared using Kaplan--Meier survival curves with log rank tests and Cox regression. Analysis was carried out using Stata version 9.

Results
=======

Incorporation of ^3^H-thymidine by primary cultures in the presence of paclitaxel were found to decrease with increasing drug concentration to a 'plateau\' value ([Figure 1](#fig1){ref-type="fig"}) from which the culture cycle time was calculated. Culture cycle times estimated using this method ranged from 2 to ⩾40 days, with a median of 10 days ([Table 1](#tbl1){ref-type="table"}). Survival times for the patients from whom tumour samples were taken, together with data for age, gender, tumour grade and treatment, are also shown in [Table 1](#tbl1){ref-type="table"}.

[Table 2](#tbl2){ref-type="table"} compares survival and culture cycle times for the different age, gender, tumour type and treatment groups. Survival varied by age (*P*=0.002) and the estimated median survival times in months were 9.5 for those aged under 30 years, 30.7 for those aged 30--50 years, 9.1 for those aged 50--59 years, 7.3 for those aged 60--69 years and 2.6 for those aged 70 years and above. There was no difference in survival by gender (the median survival times were 8.9 months for females and 8.2 months for males, *P*=0.9). Survival was also related to tumour type (*P*=0.0004, [Table 2](#tbl2){ref-type="table"}). For patients with glioblastoma, the proportion alive after 1 year was estimated to be 28%, compared with 64% for patients with astrocytoma/oligodendroglioma, 67% for patients with medulloblastoma and 31% for patients with metastatic melanoma. Some of the patients received radiotherapy (median dose 56 Gy), but data were not available for all patients. The median survival times for patients receiving radiotherapy and those not receiving radiotherapy were 12.1 and 2.6 months, respectively (*P*=0.0004). Only nine patients received chemotherapy, most of whom also received radiotherapy.

There was no evidence of variation in culture cycle times by age or gender ([Table 2](#tbl2){ref-type="table"}), but patients with astrocytomas or oligodendrogliomas had longer culture cycle times (the percentage with culture cycle times of ⩽10 days was 15%, as compared with 53% for glioblastomas, 50% for medulloblastomas and 75% for metastatic melanomas, *P*=0.04). Patients who had received radiotherapy also had longer culture cycle times (the percentage with culture cycle times ⩽10 days was 35%, compared with 58% for those who did not receive radiotherapy and 78% for those where treatment status was unknown, *P*=0.04).

Patients were divided into two groups with culture cycle times of ⩽10 days and \>10 days. Kaplan--Meier survival curves are plotted in [Figure 2A](#fig2){ref-type="fig"}. The median survival times were 5.1 months (95% CI (2.6--8.2)) and 12.5 months (95% CI (9.0--18.4)) for those with culture cycle times of ⩽10 days and \>10 days, respectively (*P*=0.0009). Those with culture cycle times ⩽10 days had a 2.4-fold increased risk of death compared with those whose culture cycle times were \>10 days (95% CI (1.4--4.2), *P*=0.001). Adjustment for age and tumour type did not explain the differences ([Table 3](#tbl3){ref-type="table"}), and adjustment for radiotherapy increased the hazard ratio slightly, giving an estimated 2.9-fold increase in risk among those with shorter culture cycle times (95% CI (1.5, 5.9), *P*=0.003), although this estimate may be biased due to missing data on radiotherapy.

For the 43 patients with glioblastoma, survival ([Figure 2B](#fig2){ref-type="fig"}) was also shorter in those with culture cycle times ⩽10 days (*P*=0.04). The median survival times were 6.5 months (95% CI (2.6--8.5)) for those with culture cycle times ⩽10 days and 9.0 (95% CI (4.7--13.7)) for those with culture cycle times \>10 days. Those with culture cycle times ⩽10 days had a 2-fold increased risk of death compared with those with culture cycle times \>10 days. Survival was also associated with age in this subgroup (*P*=0.05), but culture cycle time was not related to age. For the other tumour types, numbers were generally too small for meaningful comparisons of survival, but it was noteworthy that lower-grade gliomas had a longer median culture cycle time (16.0 days) and were associated with a longer median survival (66.4 months) than the other tumour types.

Discussion
==========

The results show a significant relationship between survival and culture cycle times derived from short-term cultures of tumour samples taken at surgery from 70 patients with brain cancer. Culture cycle times varied from 2 days to more than 40 days, and the analysis method chosen was to divide patients into two approximately equal groups with culture cycle times of ⩽10 days and \>10 days and to compare Kaplan--Meier survival curves fore each ([Figure 2](#fig2){ref-type="fig"}). These provided median survival times of 5.1 and 12.5 months, respectively, with a significant survival difference (*P*=0.0009). The study also demonstrated that culture cycle time was independent of age and tumour type. The results can be compared with those in a previous study of 16 patients with ovarian cancer treated with carboplatin, where long culture cycle times was associated with increased complete remission rate ([Marshall *et al*, 2002](#bib11){ref-type="other"}; [Baguley and Marshall, 2004](#bib1){ref-type="other"}). Re-analysis of this data using the methods employed here showed a median survival time for the ⩽10-day group of 2.9 months (95% CI (0.1--11.8)), which was significantly shorter (*P*=0.0003) than the median survival time for the \>10-day group of 25.6 months (95% CI (11.8--100)). We also have evidence for similar relationships in a larger group of ovarian cancer patients and in a group of patients with melanoma (unpublished results). These studies are the first to our knowledge to identify *in vitro* proliferation rates of primary tumour cell cultures as a potential marker for survival.

The method used here to estimate culture cycle time diverges significantly from the *T*~pot~ (potential doubling time) method that has been employed extensively in the past as a cytokinetic parameter ([Wilson *et al*, 1988](#bib19){ref-type="other"}; [Rew and Wilson, 2000](#bib15){ref-type="other"}) and deserves comment. The stathmokinetic approach employed relies on the principle that if cell cycle progression is blocked in a certain phase, the proportion of cells in that phase will increase, whereas the proportions in other phases decrease, and that the rate of change of these proportions are a function of culture cycle time. In the specific case of a mitotic poison such as paclitaxel, the number of S-phase cells in control cultures will increase exponentially with time, whereas the number of S-phase cells in drug-treated cultures will decrease with time as a consequence of depletion of the pool of G~1~-phase cells. The concentration of paclitaxel must be high enough to prevent all cell division, accounting for the shape of the dose--response curves in [Figure 1](#fig1){ref-type="fig"}. There are two methods of deriving a relationship between 'plateau\' values (*P*) for ^3^H-thymidine incorporation in these dose--response curves and culture cycle time (*T*). The first, employed here, is to use an empirical formula *T*=−3.78/(log~10~ *P*) established from a series of cell lines and making the assumption, which is reasonable for cell lines, that the culture cycle time is equal to the doubling time. The second is to base the calculation on a theoretical model for the cell cycle, and we have previously developed such a model, on the basis of the assumption that the transition from G~1~ phase to S phase is controlled by a probability function ([Basse *et al*, 2003](#bib4){ref-type="other"}). Such a model fits experimental data for a number of cell lines treated with paclitaxel and analysed using flow cytometry ([Basse *et al*, 2004a](#bib5){ref-type="other"}, [2004b](#bib6){ref-type="other"}). The theoretical model provides an equation *T*=−*x*/(log~10~ *P*), where *x* tends upwards towards 4.8, as the G~1~-phase proportion increases towards 100%. Thus, the empirical and theoretical estimates are comparable. There are potential sources of error in this approach, as there are in the *T*~pot~ approach, but the results suggest that the approach is valid.

The results from primary cultures can be compared with the wealth of published data showing a relationship between *T*~pot~ values and survival for several tumour types ([Wilson *et al*, 1988](#bib19){ref-type="other"}; [Rew and Wilson, 2000](#bib15){ref-type="other"}). Although the culture cycle times and *T*~pot~ values are quite different to each other, they both pertain to the cytokinetic properties of tumour cells, and both indicate a surprisingly wide range in culture cycle times. Unfortunately, we have insufficient data linking culture cycle times to more traditional indices of proliferation. Data for Ki-67 staining and mitotic index were available from histology reports of some of the patients, but these were was not correlated with either survival or culture cycle time (results not shown). A larger controlled study would be needed to compare culture cycle times with histological indicators of cell proliferation or with molecular markers, such as cyclin E expression ([Keyomarsi *et al*, 2002](#bib9){ref-type="other"}) and gene expression signatures ([Nutt *et al*, 2003](#bib14){ref-type="other"}). However, one interpretation of the data presented in this study is that cytokinetic properties of tumour cells may be preserved, at least initially, after tumour material is removed from the patient.

The question of why shorter culture cycle times, or shorter *T*~pot~ values, are related to poor clinical outcome still remains to be answered. Such times are not related directly to tumour growth because tumour cells are in a state of continuous turnover, with the net tumour volume doubling time usually in the order of months rather than days ([Watson, 1991](#bib18){ref-type="other"}). Shorter culture cycle times thus reflect higher rates of tumour cell turnover *in vivo*, which in turn might contribute to greater tumour aggressiveness. Rapid turnover of tumour cells may lead to the generation of a more immunosuppressive microenvironment, which could in turn be linked to poor survival ([Kim *et al*, 2006](#bib10){ref-type="other"}).

In conclusion, the overall survival of patients with brain cancers in response to therapy most likely reflects a composite of response of tumour cells and host responses to tumour, and it is clear from this study that tumour cell cytokinetics may play a major role. Other studies have demonstrated that radiotherapy and chemotherapy also contribute to survival, raising the question of whether short-term cultures could provide information on response to therapy as well as on cytokinetics. Some of the patients in this study were treated with radiotherapy ([Table 1](#tbl1){ref-type="table"}), and the median survival time for patients receiving radiotherapy (12.1 months) was longer than that for patients not receiving radiotherapy (2.6 months). Although part of this difference will reflect patient selection, much is likely to reflect the contribution of therapy. For 21 of the patients in this study, the response of 7-day cultures to radiotherapy (up to 9 Gy) was also measured ([Marshall *et al*, 2003](#bib12){ref-type="other"}), but no relationship to survival was found (results not shown). Further research will be required to develop accurate methods of assessing the relative contributions of intrinsic tumour cytokinetics and treatment to survival of patients with brain cancer.
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![Examples of ^3^H-thymidine incorporation as a function of paclitaxel concentration. Profiles are shown for patients D4 (**A**), S4 (**B**) and B6 (**C**), with designations in [Table 1](#tbl1){ref-type="table"}.](6604716f1){#fig1}

![Kaplan--Meier survival plots of patients whose culture cycle times were ⩽10 days (dashed line) and \>10 days (solid line). (**A**) All patients. (**B**) Patients with glioblastoma.](6604716f2){#fig2}

###### 

Clinical and biological data

  **Patient**   **Age (years)**   **Gender**   **Tumour type**                 **Plateau (%)**^**a**^   **Culture cycle time (days)**   **Survival (days)**^**b**^   **Radiotherapy**
  ------------- ----------------- ------------ ------------------------------- ------------------------ ------------------------------- ---------------------------- ------------------
  A1            86                M            Glioblastoma                    38                       9.0                             105                          Yes
  A2            74                M            Metastatic melanoma             75                       30.3                            559                          Yes
  B1            54                F            Glioblastoma                    41                       9.8                             271                          No
  B2            14                F            Glioblastoma                    19                       5.2                             282                          Yes
  B3            68                F            Glioblastoma                    39                       9.2                             222                          Yes
  B4            67                F            Glioblastoma                    42                       10                              267                          No
  B5            57                M            Astrocytoma, anaplastic         28                       6.8                             101                           
  B6            52                M            Glioblastoma                    89                       40.0                            489^\*^                      Yes
  C1            73                M            Glioblastoma                    78                       35.0                            399                          Yes
  D1            32                M            Medulloblastoma                 55                       14.6                            343^\*^                      Yes
  D2            54                M            Glioblastoma                    55                       14.6                            368                          Yes
  D3            7                 F            Astrocytoma, pilocytic          55                       14.6                            289                          No
  D4            69                M            Glioblastoma                    46                       11.2                            104                          Yes
  E1            36                M            Astrocytoma, anaplastic         66                       20.9                            3168                         Yes
  E2            49                M            Oligodendroglioma, anaplastic   76                       31.7                            868^\*^                      Yes
  F1            2                 M            Glioblastoma                    37                       8.8                             78                           No
  F2            72                M            Glioblastoma                    26                       6.5                             197                          Yes
  F3            74                F            Glioblastoma                    38                       9.0                             491                           
  F3            68                M            Metastatic melanoma             79                       36.9                            378                          No
  G1            43                M            Astrocytoma, anaplastic         64                       19.5                            316^\*^                      Yes
  G2            13                M            Glioblastoma                    59                       16.5                            476                          Yes
  G3            35                M            Glioblastoma, recurrent         33                       7.9                             462                           
  G2            45                M            Glioblastoma                    40                       9.5                             933                          Yes
  H1            64                M            Glioblastoma                    68                       22.6                            230                          Yes
  H2            80                F            Glioblastoma                    85                       40.0                            71                           No
  H3            73                F            Glioblastoma                    36                       8.5                             38                           No
  H4            74                M            Astrocytoma, anaplastic         78                       35.0                            22                            
  H5            38                F            Medulloblastoma                 92                       40.0                            146                          No
  H6            40                F            Oligodendroglioma               33                       7.9                             166^\*^                       
  H5            71                M            Glioblastoma                    52                       13.3                            275                          Yes
  J1            44                M            Metastatic melanoma             32                       7.6                             2                            No
  J2            32                M            Astrocytoma                     80                       40.0                            2023                         Yes
  J3            58                F            Glioblastoma                    50                       12.6                            380                          No
  J4            10                F            Medulloblastoma                 16                       4.7                             2195^\*^                      
  K1            76                F            Glioblastoma                    56                       15.0                            21                           No
  K2            49                M            Metastatic melanoma             38                       9.0                             251                          Yes
  K3            47                F            Glioblastoma                    33                       7.9                             156                          No
  K4            66                M            Glioblastoma                    27                       6.6                             101                          No
  L1            57                M            Glioblastoma                    27                       6.6                             218                          No
  L2            69                F            Glioblastoma                    16                       4.7                             46                           No
  M1            49                M            Glioblastoma                    7.3                      3.3                             111                          Yes
  M2            43                M            Metastatic melanoma             8.7                      3.6                             91^\*^                        
  M3            36                F            Medulloblastoma                 6.9                      3.3                             936^\*^                      Yes
  M4            57                M            Metastatic melanoma             11                       3.9                             18                           No
  M5            75                M            Astrocytoma, anaplastic         66                       20.9                            331                          Yes
  M6            28                M            Astrocytoma, anaplastic         54                       14.1                            219^\*^                      No
  N1            10                F            Medulloblastoma                 63                       18.8                            455^\*^                      Yes
  N2            42                M            Astrocytoma, anaplastic         49                       12.2                            1301                         Yes
  N3            50                M            Glioblastoma                    100                      40.0                            326                          Yes
  O1            57                F            Glioblastoma                    49                       12.2                            416                          Yes
  P1            77                F            Glioblastoma                    42                       10.0                            80                           No
  P2            55                M            Glioblastoma                    48                       11.9                            239                          Yes
  P3            63                M            Glioblastoma                    40                       9.5                             65                           No
  R1            65                F            Metastatic melanoma             22                       5.7                             112                          Yes
  R2            89                F            Glioblastoma                    23                       5.9                             71                           No
  R3            73                M            Glioblastoma                    17                       4.9                             71                           No
  R4            32                F            Glioblastoma                    64                       19.5                            986                          Yes
  S1            31                F            Oligodendroglioma, anaplastic   55                       14.6                            2354                         Yes
  S2            65                F            Glioblastoma                    41                       9.8                             260                          Yes
  S3            40                M            Metastatic melanoma             1.2                      2.0                             28                           No
  S4            53                M            Glioblastoma                    3.3                      2.6                             276                          Yes
  S5            63                F            Glioblastoma                    37                       8.8                             293                           
  T1            53                M            Oligoastrocytoma                58                       16.0                            6464^\*^                     No
  T2            48                F            Glioblastoma                    56                       15.0                            144                          Yes
  U1            40                F            Glioblastoma                    75                       30.3                            694^\*^                      Yes
  V1            66                F            Glioblastoma                    42                       10.0                            549                          Yes
  V2            32                F            Glioblastoma                    25                       6.3                             230                          Yes
  W2            10                M            Medulloblastoma                 11                       3.9                             69                           Yes
  W3            63                M            Glioblastoma                    71                       25.4                            230                           
  Y1            69                M            Glioblastoma                    86                       40.0                            47                           No

Results from ^3^H-thymidine incorporation assays, examples of which are shown in [Figure 1](#fig1){ref-type="fig"}.

Patients alive at the time of analysis are marked by an asterisk.

###### 

Associations between survival, culture cycle time and demographic and treatment variables

                                   **No.**   **Median culture cycle time in days (95% CI)**   **Cycle ⩽10 days, *n* (%)**   **Cycle \>10 days, *n* (%)**   **Percentage alive at 1 year (95% CI)**^**a**^    **Median survival (95% CI) in months**^**a**^
  -------------------------------- --------- ------------------------------------------------ ----------------------------- ------------------------------ ------------------------------------------------ -----------------------------------------------
  *Age (years)*                                                                                                                                                                                             
   \<30                            8         11.4 (4.5--17.2)                                 4 (50%)                       4 (50%)                        45% (11--75%)                                                        9.5^b^
   30--49                          22        10.9 (7.6--19.5)                                 11 (50%)                      11 (50%)                       62% (37--79%)                                                   30.7 (5.1--66.5)
   50--59                          12        12.0 (6.7--15.8)                                 5 (42%)                       7 (58%)                        42% (15--67%)                                                    9.1 (3.3--13.7)
   60--69                          14        9.9 (8.8--23.0)                                  7 (50%)                       7 (50%)                        14% (2--37%)                                                     7.3 (2.1--8.8)
   70+                             14        11.7 (8.2--31.0)                                 7 (50%)                       7 (50%)                        21% (5--45%)                                                     2.6 (1.2--10.9)
                                             *P*=0.9                                          *P*=0.99                                                     *P*=0.002^+^                                                             
                                                                                                                                                                                                                                    
  *Gender*                                                                                                                                                                                                  
   Male                            41        12.2 (8.9--17.5)                                 18 (44%)                      23 (56%)                       39% (24--54%)                                                    8.2 (3.6--12.4)
   Female                          29        9.8 (8.3--13.3)                                  16 (55%)                      13 (45%)                       36% (19--54%)                                                    8.9 (4.8--13.7)
                                             *P*=0.4                                          *P*=0.4                                                      *P*=0.9^+^                                                               
                                                                                                                                                                                                                                    
  *Tumour type*                                                                                                                                                                                             
   Glioblastoma                    43        9\. 8 (9.1--12.6)                                23 (53%)                      20 (47%)                       28% (16--42%)                                                    7.6 (4.7--9.1)
   Astrocytoma/oligodendroglioma   13        16.0 (13.0--27.5)                                2 (15%)                       11 (85%)                       64% (30--85%)                                                   66.4 (9.5--104.1)
   Medulloblastoma                 6         9.9 (3.3--37.8)                                  3 (50%)                       3 (50%)                        67%^b^                                                               ---^c^
   Metastatic melanoma             8         6.7 (3.1--32.4)                                  6 (75%)                       2 (25%)                        31% (5--64%)                                                     3.7 (0.1--12.4)
                                             *P*=0.06                                         *P*=0.04                                                     *P*=0.0004^+^                                                            
                                                                                                                                                                                                                                    
  *Radiotherapy*                                                                                                                                                                                            
   Yes                             37        13.3 (9.8--18.7)                                 13 (35%)                      24 (65%                        51% (34--66%)                                                   12.1 (8.5--18.4)
   No                              24        9.6 (7.3--14.0)                                  14 (58%)                      10 (42%)                       15% (4--33%)                                                     2.6 (1.5--7.2)
   Unknown                         9         8.1 (4.9--24.2)                                  7 (78%)                       2 (22%)                        46% (11--76%)                                                    9.6 (0.7--16.1)
                                             *P*=0.2                                          *P*=0.04                                                     *P*=0.0003^+^                                                            

^+^Log rank.

Calculated using life table methods.

Numbers too small for calculation.

Survival curve did not go below 50%.

###### 

Association of culture cycle time, clinical variables and survival estimated using Cox regression

                                                                      **Hazard ratio**   **95% CI**     ***P*-value**
  ------------------------------------------------------------------- ------------------ -------------- ---------------
  *Model 1: culture cycle time only*                                                                    
   *Culture cycle time (days)*                                                                          
    \>10                                                              1.0                                
    ⩽10                                                               2.4                (1.4--4.2)     0.001
                                                                                                         
  *Model 2: culture cycle time+age*                                                                     
  * Culture cycle time (days)*                                                                          
    \>10                                                              1.0                                
    ⩽10                                                               2.5                (1.4--4.4)     0.001
                                                                                                         
  * Age group (years)*                                                                                  
    \<30                                                              1.0                                
    30--49                                                            1.0                (0.4--2.9)     0.97
    50--59                                                            1.7                (0.6--5.4)     0.33
    60--69                                                            3.6                (1.2--10.4)    0.02
    70+                                                               3.4                (1.2--9.7)     0.02
                                                                                                         
  *Model 3: culture cycle time+age+tumour type*                                                         
  * Culture cycle time (days)*                                                                          
    \>10                                                              1.0                                
    ⩽10                                                               2.4                (1.3--4.4)     0.005
                                                                                                         
  * Age group (years)*                                                                                  
    \<30                                                              1.0                                
    30--49                                                            0.61               (0.20--1.9)    0.4
    50--59                                                            0.86               (0.26--2.8)    0.8
    60--69                                                            1.5                (0.47--4.6)    0.5
    70+                                                               1.4                (0.46--4.6)    0.5
                                                                                                         
  * Tumour type*                                                                                        
    Glioblastoma                                                      1.0                                
    Medulloblastoma                                                   0.15               (0.03--0.79)   0.03
    Metastatic melanoma                                               1.3                (0.54--2.9)    0.6
    Astrocytoma/oligodendroglioma                                     0.37               (0.13--1.1)    0.07
                                                                                                         
  *Model 4: culture cycle time+age+tumour type+radiotherapy (days)*                                     
  * Culture cycle time*                                                                                 
    \>10                                                              1.0                                
    ⩽10                                                               2.9                (1.5--5.9)     0.003
                                                                                                         
  * Age group (years)*                                                                                  
    \<30                                                              1.0                                
    30--49                                                            0.74               (0.25--2.2)    0.6
    50--59                                                            0.53               (0.16--1.7)    0.3
    60--69                                                            1.4                (0.47--4.5)    0.5
    70+                                                               1.8                (0.60--5.6)    0.3
                                                                                                         
  * Tumour type*                                                                                        
    Glioblastoma                                                      1.0                                
    Medulloblastoma                                                   0.21               (0.04--1.0)    0.05
    Metastatic melanoma                                               0.93               (0.38--2.3)    0.9
    Astrocytoma/oligodendroglioma                                     0.30               (0.09--0.92)   0.03
                                                                                                         
  * Radiotherapy*                                                                                       
    No                                                                1.0                                
    Yes                                                               0.32               (0.16--0.63)   0.001
    Unknown                                                           0.14               (0.05--0.43)   0.001

[^1]: Current address: Department of Neurological Surgery, University of Virginia, PO Box 800212, Charlottesville, VA 22908, USA
